Acute Myeloid Leukemia (AML) research hub

Safety of TEG001 in patients with r/r AML/high-risk MDS or r/r MM

This early-stage study is testing a new treatment called TEG001. It's for adults with certain blood cancers like acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS), or multiple myeloma (MM) that have come back or are high-risk. The main goal is to see if TEG001 is safe for people to use.

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

This study looks at a new drug, venetoclax, combined with existing treatment, azacitidine, for adults with a type of blood disorder called higher-risk Myelodysplastic Syndrome (MDS). It aims to see if this combination is safe and effective compared to azacitidine alone.

A Phase 1 Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib or Venetoclax in Participants with Relapsed/Refractory Hematologic Malignancies

A first-in-human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy in subjects with relapsed/refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome